<!DOCTYPE html>
<html  lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<script async src="https://www.googletagmanager.com/gtag/js?id=G-273DTKB5QW"></script>
<meta name="description" content="FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)" />
<meta name="dcterms.title" content="FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)" />
<meta name="dcterms.creator" content="Center for Drug Evaluation and Research" />
<meta name="dcterms.description" content="FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)" />
<meta name="dcterms.publisher" content="FDA" />
<meta name="dcterms.type" content="Article" />
<meta name="dcterms.source" content="FDA" />
<meta name="dcterms.audience" content="Caregivers, Consumers, Health Professional" />
<meta property="og:site_name" content="U.S. Food and Drug Administration" />
<meta property="og:type" content="Article" />
<meta property="og:url" content="https://www.fda.gov/drugs/drug-safety-communications/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab" />
<meta property="og:title" content="FDA to recommend additional, earlier MRI monitoring for patients" />
<meta property="og:description" content="Earlier monitoring can potentially help identify patients experiencing brain swelling or fluid buildup and help inform treatment decision-making
" />
<meta property="og:updated_time" content="Fri, 04/03/2026 - 00:00" />
<meta property="article:publisher" content="FDA" />
<meta property="article:published_time" content="Fri, 04/03/2026 - 12:19" />
<meta property="article:modified_time" content="Fri, 04/03/2026 - 00:00" />
<meta name="google-site-verification" content="tWxlDhm4ANdksJZPj7TBmHgNoMqZCnecPp0Aa2vC9XA" />
<meta name="twitter:card" content="summary_large_image" />
<meta name="twitter:site" content="@US_FDA" />
<meta property="twitter:description" content="Earlier monitoring can potentially help identify patients experiencing brain swelling or fluid buildup and help inform treatment decision-making
" />
<meta name="twitter:title" content="FDA to recommend additional, earlier MRI monitoring for patients" />
<meta name="twitter:creator" content="@US_FDA" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<script type="application/ld+json">{
    "@context": "https://schema.org",
    "@graph": [
        {
            "@type": "Article",
            "headline": "FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)",
            "name": "FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)",
            "description": "FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)",
            "datePublished": "Fri, 04/03/2026 - 12:19",
            "dateModified": "Fri, 04/03/2026 - 00:00",
            "author": {
                "@type": "Organization",
                "name": "Center for Drug Evaluation and Research"
            },
            "publisher": {
                "@type": "Organization",
                "name": "FDA"
            }
        }
    ]
}</script>
<meta property="og:image" content="https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png" />
<meta name="twitter:image" content="https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png" />
<link rel="icon" href="/themes/custom/preview/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://www.fda.gov/drugs/drug-safety-communications/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab" />
<link rel="canonical" href="https://www.fda.gov/drugs/drug-safety-communications/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab" />
<link rel="shortlink" href="https://www.fda.gov/node/426506" />
<script src="/files/google_tag/production/google_tag.script.js?tdm3ib" defer></script>

    <title>FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab) | FDA</title>
    <link rel="stylesheet" media="all" href="/files/css/css_I1lI2DYRy4WvhS49GZC8Z2v9NUFD60djX72-ZNQ0RPY.css?delta=0&amp;language=en&amp;theme=preview&amp;include=eJxNzEsOwjAMRdENBbykKJ9HZeLGJXZA2T2CQWFydUa3NFR2HZF7RfcsWhr9Odgyx045GcIx8GS8aBPNSS7mS7hv4f6YGCtOjjU5Di4Ng34MN1Xv6jA6FT4fo2-vu9YpeAPskjb1" />
<link rel="stylesheet" media="all" href="/files/css/css_B95BD3t88GaU3KJsI8NVEEoAEOpmkrFShtrB0UHHJdY.css?delta=1&amp;language=en&amp;theme=preview&amp;include=eJxNzEsOwjAMRdENBbykKJ9HZeLGJXZA2T2CQWFydUa3NFR2HZF7RfcsWhr9Odgyx045GcIx8GS8aBPNSS7mS7hv4f6YGCtOjjU5Di4Ng34MN1Xv6jA6FT4fo2-vu9YpeAPskjb1" />

    <script src="https://script.crazyegg.com/pages/scripts/0024/3700.js" async></script>
<script src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&amp;subagency=FDA&amp;sdor=fda.gov&amp;dclink=true" language="javascript" id="_fed_an_ua_tag"></script>

            <script>window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag("js", new Date());gtag("set", "developer_id.dMDhkMT", true);gtag("config", "G-273DTKB5QW", {"groups":"default","page_placeholder":"PLACEHOLDER_page_location","allow_ad_personalization_signals":false});</script>
        
  </head>
  <body class="role-anonymous path-node page-node-type-article has-glyphicons">
      <div id="quicklinks" class="sr-only display-on-focus">
        <ul class="list-inline padding-left-3 padding-right-3">
          <li><a href="#main-content" class="btn btn-default margin-top-3" tabindex="1">Skip to main content</a></li>
          <li><a href="#search-form" class="btn btn-default margin-top-3" tabindex="1">Skip to FDA Search</a></li>
          <li><a href="#section-nav" class="btn btn-default margin-top-3" tabindex="1">Skip to in this section menu</a></li>
          <li><a href="#footer" class="btn btn-default margin-top-3" tabindex="1">Skip to footer links</a></li>
        </ul>   
      </div>    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M95XGZW" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
       
  <div class="main-container container-fluid">     <div class="row">
                                                               


	
	<header class="lcds-header container-fluid" role="banner">
		                    
			<div class="row us-masthead">                            

				<div class="usa-banner col-xs-12">

					<img class="usa-banner__us-flag" src="/themes/custom/preview/assets/images/US_Flag.png" alt="U.S. flag" />

					<span>An official website of the United States government</span>

				    <a id="USMenuButton" class="collapsed" role="button" aria-expanded="false" aria-controls="USABannerMenu" href="#" data-toggle="collapse" data-target="#USABannerMenu">Here’s how you know <span class="toggle-indicator"> </span></a>

          			<div class="col-xs-12 collapse usa-banner__menu" id="USABannerMenu" aria-labelledby="USMenuButton">


						<div id="gov-banner" class="row usa-banner-content usa-grid usa-accordion-content" aria-hidden="true">
							      <div class="col-xs-12 col-sm-6 col-md-3">
							        <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-dot-gov.svg" alt="Dot gov" style="width:3em;">
									<div class="usa-media_block-body">
								      <p><strong>The .gov means it’s official.</strong><br>Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.</p>
								    </div>
							      </div>
							      <div class="col-xs-12 col-sm-6 col-md-3">
							        <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-https.svg" alt="SSL" style="width:3em;">
							        <div class="usa-media_block-body">
								         <p><strong>The site is secure.</strong><br> The <strong>https://</strong> ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.</p>
							        </div>
							      </div>
						</div>
					</div>

				</div>
			</div> 			<div class="row fda-masthead">
							<div class="col-xs-4 col-md-8 fda-masthead__fda-logo"> 
					<a href="/" title="FDA Homepage">
            <picture>
              <!-- Set media breakpoint to value equivalent to $screen-md -->
              <source media="(min-width:992px)" srcset="/themes/custom/preview/assets/images/gov-fda-new-white.svg">
              <img src="/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg" height="40px" alt="U.S. Food and Drug Administration logo">
            </picture>
          </a>
       	</div>
				
        <div class="col-xs-8 col-md-4">
        <ul class="fda-masthead__item-list">
            <li>
                <button id="btn-search" class="btn btn-default btn-sm fda-masthead__btn-search" aria-expanded="false" aria-controls="search-form" title="Open search bar">
					<span class="fa fa-search" aria-hidden="true">&nbsp;</span>
			    	<span class="fda-masthead__btn-label">Search</span>
				</button>
            </li>
            <li>
                <button id="menu-btn" class="btn btn-default btn-sm fda-masthead__btn-menu collapsed" href="#primary-nav" data-toggle="collapse" aria-expanded="true">
                    <span class="fa fa-bars" aria-hidden="true">&nbsp;</span>
                    <span class="fda-masthead__btn-label">Menu</span>
                </button>
            </li>
        </ul>
		</div>
							
						<form class="fda-masthead__search sr-only" id="search-form" aria-hidden="true" role="search" action="/search" method="GET" accept-charset="UTF-8">
							<div class="search-popover" id="search-popover">
								<div class="input-group pull-right" id="search-group">
									<label class="sr-only" for="search-query">Search FDA</label>
									
									<input class="form-control search-input" tabindex="-1" id="search-query" name="s" aria-autocomplete="list" aria-haspopup="true" title="Enter the terms you wish to search for." placeholder="Search FDA"  type="text" /> 
									
									<span class="input-group-btn" id="input-group-btn">
										
										<button type="submit" type="button" class="btn btn-danger search-btn" id="search-btn" tabindex="-1" title="Search"><span class="fa fa-search" aria-hidden="true"><span class="sr-only">Submit search</span></span></button>

									</span>

								</div>
							</div>
																				
						</form>					

			</div> 
		<nav id="primary-nav" class="lcds-primary-nav row collapse">					<div class="col-md-5 col-lg-4">
						<section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
							<h2 class="lcds-primary-nav__group-heading">Featured</h2>
							<ul class="lcds-primary-nav__list lcds-primary-nav__list--featured">
								<li class="lcds-primary-nav__list-item"><a href="https://www.safetyreporting.hhs.gov/smarthub#/" title="Report a Problem with an FDA Regulated Product">Report a Product Problem</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/about-fda/contact-fda">Contact FDA</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/regulatory-information/search-fda-guidance-documents">FDA Guidance Documents</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/safety/recalls-market-withdrawals-safety-alerts">Recalls, Market Withdrawals and Safety Alerts</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/news-events/newsroom/press-announcements">Press Announcements</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters">Warning Letters</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/advisory-committees">Advisory Committees</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/fda-en-espanol">En Espa&#241ol</a></li>
							</ul>
						</section>
					</div>

					<div class="col-md-7 col-lg-8">
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Products</h2>
            <ul class="lcds-primary-nav__list">
							<li class="lcds-primary-nav__list-item"><a href="/food">Food</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/drugs">Drugs</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/medical-devices">Medical Devices</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/radiation-emitting-products">Radiation-Emitting Products</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/vaccines-blood-biologics">Vaccines, Blood, and Biologics</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/animal-veterinary">Animal and Veterinary</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/cosmetics">Cosmetics</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/tobacco-products">Tobacco Products</a></li>
            </ul>
          </section>
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Topics</h2>
            <ul class="lcds-primary-nav__list">
							<li class="lcds-primary-nav__list-item"><a href="/about-fda">About FDA</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/combination-products">Combination Products</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/regulatory-information">Regulatory Information</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/safety">Safety</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/emergency-preparedness-and-response">Emergency Preparedness</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/international-programs">International Programs</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/news-events">News and Events</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/training-and-continuing-education">Training and Continuing Education</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations">Inspections and Compliance</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/science-research">Science and Research</a></li>
            </ul>
          </section>
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Information For</h2>
            <ul class="lcds-primary-nav__list">
	            <li class="lcds-primary-nav__list-item"><a href="/consumers">Consumers</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/patients">Patients</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/industry">Industry</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/health-professionals">Health Professionals</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/federal-state-local-tribal-and-territorial-officials">Federal, State and Local Officials</a></li>
            </ul>
          </section>
					</div>
	      </nav>
    </header>

<div class="col-xs-12 block-prev-message">
	<div data-drupal-messages-fallback class="hidden"></div>

</div>

                              
                                                                     <section id="block-entityviewcontent-15" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
    <ol class="lcds-breadcrumb visible-md visible-lg">
          <li >
                  <a href="/">Home</a>
              </li>
          <li >
                  <a href="/drugs">Drugs</a>
              </li>
          <li >
                  <a href="/drugs/drug-safety-and-availability">Drug Safety and Availability</a>
              </li>
          <li >
                  <a href="/drugs/drug-safety-and-availability/drug-safety-communications">Drug Safety Communications</a>
              </li>
          <li >
                  <a class="current-link">FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)</a>
              </li>
      </ol>




<ol class="lcds-breadcrumb visible-sm visible-xs">
  <li>
    <a href="/drugs/drug-safety-and-availability/drug-safety-communications" title="Drug Safety Communications">
     Drug Safety Communications
    </a>
  </li>
</ol>

  </section>

<section id="block-entityviewcontent" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
<div class="lcds-section-nav-container hidden-md hidden-lg">
<a class="lcds-button--expandable collapsed hidden-md hidden-lg" data-toggle="collapse" href="#section-nav" >In this section</a>

<nav id="section-nav" class="lcds-card lcds-section-nav lcds-section-nav hidden-md hidden-lg collapse">

    <ul class="lcds-section-nav__list">

      <li>

              <a href="/drugs/drug-safety-and-availability/drug-safety-communications" title="Drug Safety Communications" class="lcds-section-nav__section-link lcds-section-nav__link lcds-section-nav__parent-link visible-xs-block visible-sm-block">
                                        Drug Safety Communications
                    </a>

                        <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_5 js-view-dom-id-718c247c6a68f4e71fa390bf7c97d160af9214bc6abd5109d9405aed8020583e">
  
    
      
  
          </div>
</div>


                        <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_2 js-view-dom-id-6f2b98a2f83f1ff622a5eb9f75382eb9076f1d73da2ba8301053a59c1c557128">
  
    
      
  
          </div>
</div>


      </li>

    </ul>

</nav>
</div>

  </section>






                                
      <main>

                                 <article id="main-content" class="article main-content container-fluid" role="article">
          
                                                                <header class="row content-header">
                         <section id="block-entityviewcontent-2" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
<div class="col-sm-12 col-md-8 col-md-offset-2">

  <h1 class="content-title text-center">FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)</h1>
  
  					<p class="article-subtitle text-center">Earlier monitoring can potentially help identify patients experiencing brain swelling or fluid buildup and help inform treatment decision-making
</p>
	
 
</div>

  </section>






                      </header>
                              
                                                          
                              <aside class="col-md-2" role="complementary">
                  <section id="block-entityviewcontent-3" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

        <div class="region region-">
        <nav id="section-nav"class="lcds-card lcds-section-nav lcds-section-nav--side hidden-xs hidden-sm">
      <ul class="lcds-section-nav__list lcds-section-nav--side__list">
        <li>

                    <a href="/drugs/drug-safety-and-availability/drug-safety-communications" class="lcds-section-nav__link lcds-section-nav--side__link lcds-section-nav__parent-link lcds-section-nav--side__parent-link">
                                        Drug Safety Communications
                      </a>

          
                        <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_4 js-view-dom-id-6fb74f6d0486059d8e4586a5b0ff039ad7ecb30cfeb175356093f9195e15f865">
  
    
      
  
          </div>
</div>


                        <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_1 js-view-dom-id-56f190e122c4786bac3fd80a7b2bc6d3683228a7b10ecc2f43a115e584c7778e">
  
    
      
  
          </div>
</div>


        </li>
      </ul>
    </nav>
    </div>

  </section>


                </aside>
              
                                                          
              <div class="col-md-8" role="main">

                            
                            
                            
                            
                                              
  
<p><a href="/media/188468/download?attachment" data-entity-type="media" data-entity-uuid="a9ad6b9d-d356-43c9-8cc4-1fb9a9ed46f8" data-entity-substitution="media_download" title="FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)">Drug Safety Communication</a> (PDF - 234 KB)</p><p>08-28-2025 FDA Drug Safety Communication</p><p>   
</p><div title="What Safety Concern Is FDA Announcing?" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad75e62">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad75e62" aria-controls="69fa93ad75e62">What Safety Concern Is FDA Announcing?</a>
		</h2>
	</div>
    <div id="69fa93ad75e62" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad75e62">
		<div class="panel-body">
			<p>The U.S. Food and Drug Administration (FDA) is recommending an additional, earlier magnetic resonance imaging (MRI) monitoring prior to the 3<sup>rd</sup> infusion for patients with Alzheimer’s disease taking Leqembi (lecanemab). The earlier monitoring can identify individuals with amyloid-related imaging abnormalities with edema (ARIA-E), which is characterized by brain swelling or fluid buildup. ARIA-E is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, can occur and there have been deaths.</p><p>The Alzheimer’s disease community has been aware of ARIA-E associated with Leqembi, and current prescribing information recommends MRI imaging before the 5<sup>th</sup>, 7<sup>th</sup>, and 14<sup>th</sup> infusions. However, after an in-depth analysis of this safety issue, the Agency has determined that an additional monitoring MRI prior to the 3<sup>rd</sup> infusion can potentially help identify ARIA-E events earlier.</p><p>ARIA-E can progress after initial detection on MRI. Identifying patients with ARIA-E can lead health care professionals, patients, and their families to delay or discontinue Leqembi treatment to potentially mitigate these serious and, in some cases, fatal events.</p><p>
		</p></div>
	</div>
</div>   
<div title="What Is FDA Doing?" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad76cef">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad76cef" aria-controls="69fa93ad76cef">What Is FDA Doing?</a>
		</h2>
	</div>
    <div id="69fa93ad76cef" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad76cef">
		<div class="panel-body">
			<p>We are requiring the prescribing information of Leqembi (lecanemab) to include an earlier monitoring MRI between the 2<sup>nd</sup> and 3<sup>rd</sup> infusion. This revised language will be in the monitoring schedule (Section 2.3) of the prescribing information. In the meantime, we want to bring public attention to this issue.</p><p>
		</p></div>
	</div>
</div>   
<div title="What Is Leqembi (lecanemab)?" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad76d90">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad76d90" aria-controls="69fa93ad76d90">What Is Leqembi (lecanemab)?</a>
		</h2>
	</div>
    <div id="69fa93ad76d90" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad76d90">
		<div class="panel-body">
			<p>Leqembi (lecanemab) is an amyloid beta-directed antibody that FDA approved in 2023 to slow the progression of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia stage of disease. Leqembi is an antibody infusion that removes beta-amyloid from the brain. Beta-amyloid is a protein fragment that plays an important role in the development of Alzheimer’s disease by forming deposits in the brain called plaques and disturbing brain functioning.</p><p>Symptoms of dementia include the loss of memory, problem-solving, and ability to think clearly which can interfere with daily life. Alzheimer’s disease is the most common type of dementia. It is a progressive, irreversible disease that typically affects people aged 60 or older. In 2020, there were approximately 6.9 million people living with Alzheimer’s disease in the United States, and it is the 7<sup>th</sup> leading cause of death among U.S. adults.<sup>1</sup></p><p>
		</p></div>
	</div>
</div>    
<div title="What Should Patients and Caregivers Do?" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad76e3e">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad76e3e" aria-controls="69fa93ad76e3e">What Should Patients and Caregivers Do?</a>
		</h2>
	</div>
    <div id="69fa93ad76e3e" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad76e3e">
		<div class="panel-body">
			<p>Patients who have recently started Leqembi treatment should ask their health care professional about MRI monitoring for ARIA-E between the 2<sup>nd</sup> and 3<sup>rd</sup> infusion. Patients should contact their health care professional or go to the nearest hospital emergency room right away if they experience symptoms of ARIA-E, including headache, confusion, dizziness, vision changes, nausea, difficulty walking, or seizures. If patients do not have the ability to reach out to their health care professionals, their caregivers should do so on their behalf.</p><p>
		</p></div>
	</div>
</div>   
<div title="What Should Health Professionals Do? " open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad76ee7">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad76ee7" aria-controls="69fa93ad76ee7">What Should Health Professionals Do? </a>
		</h2>
	</div>
    <div id="69fa93ad76ee7" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad76ee7">
		<div class="panel-body">
			<p>Health care professionals should be aware of the new recommendations and perform monitoring MRIs on patients between the 2<sup>nd</sup> and 3<sup>rd</sup> Leqembi infusions. Health care professionals should advise patients (or their caregivers) to immediately contact them if they experience ARIA-E symptoms, such as headache, confusion, dizziness, vision changes, nausea, aphasia, weakness or seizure. In this case, health care professionals should order urgent MRIs.</p><p>If ARIA-E is diagnosed, health care professionals should discuss with patients and caregivers the potential need to delay or discontinue Leqembi treatment. Please refer to dose suspension criteria in the approved USPI in Section 2.3 Table 1. ARIA-E, with or without symptoms, can progress after initial detection on MRI.</p><p>
		</p></div>
	</div>
</div>   
<div title="What Did FDA Find?" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad76f53">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad76f53" aria-controls="69fa93ad76f53">What Did FDA Find?</a>
		</h2>
	</div>
    <div id="69fa93ad76f53" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad76f53">
		<div class="panel-body">
			<p>During routine pharmacovigilance, FDA identified six deaths early in treatment, which prompted an in-depth analysis of serious and fatal outcomes related to ARIA-E before the 5<sup>th</sup> Leqembi infusion.</p><p>In the analysis, FDA identified 101 cases of serious ARIA-E* (see Data Summary). Of these case reports, two (2%) occurred between the 2<sup>nd</sup> and 3<sup>rd</sup> infusion, 22 (22%) occurred between the 3<sup>rd</sup> and 4<sup>th</sup> infusion, 41 (40%) occurred between the 4<sup>th</sup> and 5<sup>th</sup> infusion, and 36 (36%) occurred after the 5th infusion.</p><p>In total, 24 cases of serious ARIA-E occurred before the 4<sup>th</sup> infusion, all of whom showed symptoms prompting an earlier unscheduled MRI for clinical assessment. This case review did not capture asymptomatic ARIA-E patients who were not identified until a later timepoint during the regularly scheduled MRIs, potentially underestimating the rate of ARIA-E earlier in the course of treatment.</p><p>Patients with ARIA-E can have symptom or imaging progression after initial detection on MRI. As such, it is important to detect these patients early, both with clinical assessment and MRI imaging, to determine whose treatment may need to be delayed or discontinued.</p><p>
		</p></div>
	</div>
</div>   
<div title="Data Summary" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad76fff">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad76fff" aria-controls="69fa93ad76fff">Data Summary</a>
		</h2>
	</div>
    <div id="69fa93ad76fff" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad76fff">
		<div class="panel-body">
			<p>During routine pharmacovigilance, FDA identified six fatal cases of amyloid related imaging abnormalities with edema (ARIA-E) early in treatment. These fatalities prompted an in-depth analysis of serious and fatal outcomes of ARIA-E occurring prior to the 5<sup>th</sup> infusion of Leqembi (lecanemab). This analysis included data from FDA Adverse Event Reporting System (FAERS) reports, literature, and information requested from the applicant.</p><p>In the in-depth analysis, FDA identified 101 cases of serious ARIA-E in FAERS. Of these case reports, two (2%) occurred between the 2<sup>nd</sup> and 3<sup>rd</sup> infusions, 22 (22%) occurred between the 3<sup>rd</sup> and 4<sup>th</sup> infusions, 41 (40%) occurred between the 4<sup>th</sup> and 5<sup>th</sup> infusions, and 36 (36%) occurred after the 5<sup>th</sup> infusion.</p><p>In total, 24 cases of serious ARIA-E occurred before the 4<sup>th</sup> infusion. All 24 patients diagnosed with ARIA-E before the 4<sup>th</sup> infusion showed symptoms, which prompted an earlier unscheduled MRI for clinical assessment. This case review does not capture asymptomatic patients who may have had ARIA before the 3<sup>rd</sup> infusion but were not identified until a later timepoint during the regularly scheduled MRIs, potentially underestimating the rate of ARIA-E earlier in the course.</p><p>FDA also completed a review of the six fatal cases. Of the six fatalities identified in the original review, only one was initially asymptomatic and identified on the first monitoring MRI (i.e., prior to the 5<sup>th</sup> infusion). The remaining five developed symptoms within 0-8 days of their most recent infusion prompting urgent MRIs. Four of these cases developed symptoms after the 3<sup>rd</sup> infusion, and the last case developed symptoms after the 4<sup>th</sup> infusion. The four fatalities that occurred shortly following the 3<sup>rd</sup> infusion suggest a developing process that was likely already present at the time of the infusion, given the severity of symptoms and relatively rapid onset after the 3<sup>rd</sup> infusion. Earlier identification of ARIA-E may lead to a delay or discontinuation of Leqembi treatment to potentially mitigate serious and, in some cases, fatal events.</p><p>
		</p></div>
	</div>
</div>   
<div title="What Is My or My Loved One’s Risk?" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad7709f">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad7709f" aria-controls="69fa93ad7709f">What Is My or My Loved One’s Risk?</a>
		</h2>
	</div>
    <div id="69fa93ad7709f" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad7709f">
		<div class="panel-body">
			<p>All medicines may have side effects even when used correctly as prescribed. Patients may be at higher risk of ARIA-E due to specific genetic factors or other underlying medical conditions. However, people respond differently to medicines. As a result, we cannot determine the exact likelihood of someone experiencing ARIA-E or other side effects from taking Leqembi. Talk to your health care professional(s) if you have questions or concerns about this medication’s risks.</p><p>
		</p></div>
	</div>
</div>    
<div title="How Do I Report Side Effects from Leqembi? " open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad7713c">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad7713c" aria-controls="69fa93ad7713c">How Do I Report Side Effects from Leqembi? </a>
		</h2>
	</div>
    <div id="69fa93ad7713c" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad7713c">
		<div class="panel-body">
			<p>To help FDA track safety issues with medicines, we urge patients and health care professionals to report side effects involving Leqembi or other medicines to the <a href="/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program" data-entity-type="node" data-entity-uuid="0785221e-cef4-4465-8621-b77dcb1032b6" data-entity-substitution="canonical" title="MedWatch: The FDA Safety Information and Adverse Event Reporting Program">FDA MedWatch</a> program using the information in the “Contact FDA” box at the bottom of this page.</p><p>
		</p></div>
	</div>
</div>   
<div title="How Can I Get New safety Information on Medicines I’m Prescribing or Taking?" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad771bd">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad771bd" aria-controls="69fa93ad771bd">How Can I Get New safety Information on Medicines I’m Prescribing or Taking?</a>
		</h2>
	</div>
    <div id="69fa93ad771bd" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad771bd">
		<div class="panel-body">
			<p>&nbsp;You can sign up for <a href="https://public.govdelivery.com/accounts/USFDA/subscriber/new">email alerts</a> about Drug Safety Communications on medicines or medical specialties of interest to you.</p><p>
		</p></div>
	</div>
</div>   
<div title="Facts about Leqembi" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad77282">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad77282" aria-controls="69fa93ad77282">Facts about Leqembi</a>
		</h2>
	</div>
    <div id="69fa93ad77282" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad77282">
		<div class="panel-body">
			<ul><li>Leqembi (lecanemab) is an amyloid beta-directed antibody that FDA approved in 2023 to slow disease progression in patients with Alzheimer’s diseases. It is indicated for patients with mild cognitive impairment or mild dementia stage of disease.</li><li>It is an antibody infusion that removes beta-amyloid from the brain.</li><li>The recommended dosage is 10 mg/kg that must be diluted then administered as an intravenous infusion over approximately one hour, once every two weeks.</li><li>The most common reactions include infusion-related reactions, ARIA-H, ARIA-E, and headache.</li><li>Leqembi can lead to serious and potentially fatal symptoms of amyloid related imaging abnormalities with edema (ARIA-E) (i.e., brain swelling or fluid buildup).</li><li>ARIA-E may present as headache, confusion, dizziness, vision changes, nausea, aphasia, weakness, or seizure. However, many patients do not have symptoms.</li><li>To identify patients experiencing ARIA-E, FDA now recommends MRI imaging before the 3<sup>rd</sup>, 5<sup>th</sup>, 7<sup>th</sup>, and 14<sup>th</sup> infusions. Patients should also obtain a recent MRI (within one year before starting treatment) for a baseline comparison.</li></ul><p>
		</p></div>
	</div>
</div>   
<div title="References" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa93ad772fd">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa93ad772fd" aria-controls="69fa93ad772fd">References</a>
		</h2>
	</div>
    <div id="69fa93ad772fd" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa93ad772fd">
		<div class="panel-body">
			<p id="ref1"><sup>1</sup> Centers for Disease Control and Prevention. Alzheimer’s Disease and Dementia. <a href="https://www.cdc.gov/alzheimers-dementia/about/alzheimers.html">https://www.cdc.gov/alzheimers-dementia/about/alzheimers.html</a>. Accessed July 14, 2025.</p><p>
		</p></div>
	</div>
</div><p><strong>Related Information</strong></p><p><a href="/consumers/health-education-resources/alzheimers-disease" data-entity-type="node" data-entity-uuid="a6dc0fab-027c-45ed-9f85-158adb294a3e" data-entity-substitution="canonical" title="Alzheimer's Disease">Alzheimer’s Disease&nbsp;</a><br><a href="/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease" data-entity-type="node" data-entity-uuid="3841a95f-c64b-4937-9879-88e6adeac388" data-entity-substitution="canonical" title="FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease">FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease&nbsp;</a><br><a href="https://www.cdc.gov/alzheimers-dementia/about/alzheimers.html">Alzheimer’s Disease and Dementia</a></p><p><strong>Contact FDA</strong><br><strong>For More Info</strong><br>855-543-DRUG (3784) and press 4<br><a href="mailto:druginfo@fda.hhs.gov">druginfo@fda.hhs.gov</a></p><p>&nbsp;</p><p><strong>Report a Serious Problem to MedWatch</strong><br>Complete and submit the report <a href="https://www.accessdata.fda.gov/scripts/medwatch/">Online</a>.&nbsp;<br><a href="https://www.fda.gov/about-fda/forms/medwatch-consumer-voluntary-reporting-pdf" title="MEDWATCH Consumer Voluntary Reporting (PDF)">Download form</a> or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.</p>

<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->
<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->



              
                                            
              
            </div>

                                                  
                          <aside class="col-md-2" role="complementary">
                <section id="block-entityviewcontent-4" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

<div class="region region-">
  <aside class="lcds-card lcds-card--border-top">
    <ul role="menu" class="lcds-description-list">
      
                            


























  <li role="menuitem" class="node-current-date lcds-description-list__item">
    <div>
      <h2 class="lcds-description-list__item-heading">Content current as of:</h2>
      <p class="lcds-description-list__item-text"><time datetime="2026-04-03T00:00:00Z">04/03/2026</time>
</p>
    </div>
  </li>
              
              
<li role="menuitem" class="lcds-description-list__item">  
	<div>
		
		 <h2 class="lcds-description-list__item-heading">Regulated Product(s)</h2>
		 <ul role="menu" class="lcds-metadata-list">
						  <li role="menuitem">Drugs</li>
			  			     			  						              
			
			
			
			
						  <li role="menuitem">Prescription Drugs</li>
			  			     			  			  
			
			
			
					</ul>
	 
			     
						       

			  
						  

			  
						 
	</div>
</li>   

    </ul>

  </aside>
</div>


  </section>


              </aside>
            
                 </article>        
      </main>

    </div>  </div>
<div id="fda-survey-comments"></div>
<script src=https://touchpoints.app.cloud.gov/touchpoints/0eb673d9.js async></script>
<button class="btn btn-primary btn-vertical" id="survey-btn">Feedback</button>
<script src=https://touchpoints.app.cloud.gov/touchpoints/d45bb814.js async=""></script>
                <div class="region region-subscribe">
    <section id="block-entityviewcontent-5" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

  </section>


  </div>

  
      <footer id="footer" class="lcds-footer container-fluid">
        
    <div class="row lcds-footer__primary">
    <nav class="text-center">
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/about-fda/about-website/fdagov-archive" >FDA Archive</a></li>
          <li><a href="/about-fda" >About FDA</a></li>
          <li><a href="/about-fda/about-website/internet-accessibility" >Accessibility</a></li>
        </ul>
      </div>
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/about-fda/visitor-information" >Visitor Information</a> </li>
          <li><a href="/about-fda/about-website/website-policies" >Website Policies / Privacy</a></li>
          <li><a href="/about-fda/jobs-and-training-fda/no-fear-act" >No FEAR Act</a></li>
          <li><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure Policy</a></li>
        </ul>
      </div>
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/regulatory-information/freedom-information" title="Freedom of Information Act">FOIA</a></li>
          <li><a href="https://www.hhs.gov/" title="Health and Human Services" target="_blank">HHS.gov</a></li>
          <li><a href="https://www.usa.gov/" target="_blank">USA.gov</a></li>
        </ul>
      </div>
    </nav>
  </div>
    <div class="row lcds-footer__secondary">
    <div class="col-sm-12 col-md-6 col-lg-4 lcds-footer__social-links">
      <a href="/about-fda/contact-fda" class="btn btn-default btn-md">Contact FDA</a>
      <a href="https://www.facebook.com/FDA" title="Follow FDA on Facebook" class="no-disclaimer"> 
        <span class="fa fa-facebook fa-2x" aria-hidden="true">
          <span class="sr-only">Follow FDA on Facebook</span> 
        </span>
      </a>
      <a href="https://x.com/US_FDA" title="Follow FDA on X" class="no-disclaimer">
        <svg class="icon-svg-inline fa-2x" aria-hidden="true">
          <use href="/themes/custom/preview/assets/images/fa-icons.svg#icon-x-twitter">
        </svg>
        <span class="sr-only">Follow FDA on X</span>
      </a>
      <a href="https://instagram.com/FDA" title="Follow FDA on Instagram" class="no-disclaimer">
        <span class="fa fa-instagram fa-2x" aria-hidden="true"> 
          <span class="sr-only">Follow FDA on Instagram</span>
        </span>
      </a>
      <br class='visible-xs-inline'/>
      <a href="https://www.linkedin.com/company/fda/" title="Follow FDA on LinkedIn" class="no-disclaimer">
        <span class="fa fa-linkedin fa-2x" aria-hidden="true"> 
          <span class="sr-only">Follow FDA on LinkedIn</span>
        </span>
      </a>
      <a href="https://youtube.com/@US_FDA" title="View FDA videos on YouTube" class="no-disclaimer">
        <span class="fa fa-youtube fa-2x" aria-hidden="true"> 
          <span class="sr-only">View FDA videos on YouTube</span>
        </span>
      </a>
      <a href="/about-fda/contact-fda/subscribe-podcasts-and-news-feeds" title="Subscribe to FDA RSS feeds">
        <span class="fa fa-rss fa-2x" aria-hidden="true">
          <span class="sr-only">Subscribe to FDA RSS feeds</span>
        </span>
      </a>
    </div>
    <a href="/" title="FDA Homepage">
        <div class="visible-lg-block col-lg-4 text-center">
          <img src="/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg" height="60px" alt="Food and Drug Administration Logo">
        </div>
    </a>
    <div class="col-sm-12 col-md-6 col-lg-4 text-center lcds-footer__contact-number">
      <span class="fa fa-phone" aria-hidden="true"> </span> 
     <span class="sr-only">Contact Number</span>
      1-888-INFO-FDA (1-888-463-6332)
    </div>
  </div>
  
      <!--END WEBSITE FEEDBACK SNIPPET-->
  

    </footer>
    <a href="" id="btn-top" class="btn btn-primary btn-top"><span class="sr-only">Back to </span>Top</a>
  

  </div>

    
    <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/426506","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"fda_ckeditor_enhancements":{"basePath":"modules\/custom\/fda_ckeditor_enhancements"},"google_analytics":{"account":"G-273DTKB5QW","trackOutbound":true,"trackMailto":true,"trackTel":true,"trackDownload":true,"trackDownloadExtensions":"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip"},"bootstrap":{"forms_has_error_value_toggle":1,"modal_animation":1,"modal_backdrop":"true","modal_focus_input":1,"modal_keyboard":1,"modal_select_text":1,"modal_show":1,"modal_size":"","popover_enabled":1,"popover_animation":1,"popover_auto_close":1,"popover_container":"body","popover_content":"","popover_delay":"0","popover_html":0,"popover_placement":"right","popover_selector":"","popover_title":"","popover_trigger":"click"},"ajax":[],"user":{"uid":0,"permissionsHash":"1b1b521ce0efd787b9481ef00f514b542eb396217a4d74c357d2ecd6b6b52a2d"}}</script>
<script src="/files/js/js_xP2P-a2AfusuVTFqrD8uHKMSZ46FoZMpbkc6_ORS8xM.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=preview&amp;include=eJxdjtEKwjAMRX9oo74I_k3J0hiLXROSMJlfL1Ms4uM9JOdeFuFGGTq0PSp64j8wqdFW6ZG4yQJtdrSq4dMiEh4GmlRUNrLpWiDjnUoNsUz9Bh1ppR6eAFGsVOk5hA-738QCpdDnSVZt9ThPR5Pn8-nyA8cCNHjuxDxAAX1Lvnlo59H4Ai47WJ8"></script>

  <script type="text/javascript"  src="/VSlrlmgubQttxfPEfQ/Li7tkShpS4p6Vp/ahssI1QC/NQ/0mZGl5fUAB"></script></body>
</html>
